Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide (GeNOsyl) in PAH and PH-IPF
NCT01265888Phase 2Completed
- Sponsor
- Genomatica
- Start
- Mar 2011
- Primary completion
- Sep 2016
- Modality
- Transdermal Patches, Inhalation Devices, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of Nitric oxide-releasing solution in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) (3 arms), sponsored by Genomatica. Primary endpoint: Minimally and Maximum Effective Doses of Inhaled Nitric Oxide at 3 hours. Started Mar 2011; status: completed.
02
Drugs
Nitric oxide-releasing solution
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT01265888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265888.